http://www.mmm-online.com/financial/topic/11591/ Articles tagged with Financial from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze. http://www.mmm-online.com/boehringer-pradaxa-tradjenta-launches-face-economic-headwind/article/254520/ Wed, 15 Aug 2012 15:45:00 GMT The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze. MMM Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year. http://www.mmm-online.com/sanofi-braces-for-patent-cliff-impact/article/227180/ Thu, 09 Feb 2012 21:51:21 GMT Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year. MMM Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip. http://www.mmm-online.com/jj-sales-up-but-earnings-wiped-out-by-settlements-product-liability-and-recall-costs/article/224544/ Tue, 24 Jan 2012 20:56:32 GMT Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip. MMM Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected. http://www.mmm-online.com/prolia-xgeva-fall-short-of-analysts-q3-sales-forecasts/article/215223/ Tue, 25 Oct 2011 03:55:04 GMT Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected. MMM Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30. http://www.mmm-online.com/company-news-johnson-johnson-forest-labs-and-berkery-noyes/article/214691/ Tue, 18 Oct 2011 19:32:08 GMT Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30. MMM AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK. http://www.mmm-online.com/uk-pr-pitch-could-portend-us-acquisitions-for-astrazeneca/article/205305/ Tue, 14 Jun 2011 19:43:18 GMT AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK. MMM Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says. http://www.mmm-online.com/which-pfizer-brands-could-stay-go-in-a-sell-off/article/198422/ Tue, 15 Mar 2011 21:39:48 GMT Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says. MMM Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation. http://www.mmm-online.com/merck-glaxosmithkline-earnings-reflect-product-difficulties/article/195661/ Thu, 03 Feb 2011 20:44:04 GMT Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation. MMM